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Edited by Hans-Dieter KlenkAbstract RNA interference (RNAi) has become one of the most
powerful and popular approach on gene silencing in clinical re-
search study especially in virology due to the gene-speciﬁc sup-
pression property of small interfering RNA (siRNA). In this
report, we demonstrate that expression of vector-mediated small
hairpin RNA (shRNA) against human immunodeﬁciency virus
type 1 (HIV-1) integrase (IN), one of the three important en-
zymes in HIV infection by controlling the integration of viral
RNA to host DNA, could suppress the protein synthesis of
EGFP-tagged IN in HeLa cell model eﬃciently. Furthermore,
we show that IN shRNA can successfully reduce the HIV parti-
cles production in 293T cells at the level similar to the positive
control of HIV-1 tat shRNA. These results provide the therapeu-
tic possibility of HIV replication using RNAi against HIV-1
integrase.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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RNA interferences; Integrase1. Introduction
Integration of HIV genome into host DNA is a crucial step
in HIV infection. It is absolutely required for viral transcrip-
tion, translation and replication [1,2]. This ﬁnal event is cata-
lyzed by HIV-1 integrase (IN) [3] and a functional integrase
is necessary for successful virus infection. Besides the function
of integration, integrase can act as a co-factor with reverse
transcriptase in the reserve transcription process [4,5]. Because
of the high selectivity due to the fact that there is no known
human homologue, HIV-1 integrase is one of the important
targets for development of anti-HIV drugs. Although there
are two small molecules that are undergoing clinical trial [6]
as IN inhibitors [7,8], the development of therapeutic IN inhib-
itors suitable for clinical usage is still limited. Recently, the dis-
covery of RNA interference (RNAi) provides a powerful way
for functional genomic and disease therapeutic study, espe-
cially in the ﬁeld of oncology and virology [9–12]. RNAi is a
gene suppression mechanism through the cleavage of mRNA
through the cooperation of Dicer and a 21nt short sequence*Corresponding author. Fax: +852 2603 7246.
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in the study of HIV inhibition against diﬀerent viral proteins
such as regulatory proteins: Tat, Rev, co-repectors: CCR5
and CXCR4, etc. [13–16]. Here, we provide evidence to show
that the HIV-IN coding region can be one of the potent targets
of RNAi for suppression of HIV replication.2. Materials and methods
2.1. Construction of EGFP-integrase expression vector
Wild-type HIV-1 integrase from a recombinant expression clone [17]
was fused with enhanced green ﬂuorescent protein (EGFP) at the N-
terminal by cloning into pEGFP-C1 expression vector (Clontech)
using PCR with appropriate primers to provide a reporter system for
monitoring the RNAi eﬀect.2.2. shRNA design and plasmid construction
Small hairpin RNA (shRNA) expression vector pSilencer 2.0-U6
(Ambion, USA) was used to trigger RNAi. HIV-IN coding sequence
(GeneBank accession no. AF078150) was submitted to the Ambion
siRNA Target Finder website (http://www.ambion.com/tecchlib/misc/
siRNA_ﬁnder.html) for siRNA prediction. Four of eighty-four sug-
gested candidates directed against IN were selected. The nucleotide se-
quences of the siRNA target sites in the HIV-1 IN gene were as
follows: IN shRNA1, 5 0-GGCCCAAGAAGAACATGAG-3 0 (nucleo-
tides [nt] 19–37); IN shRNA2, 5 0-CCTACCACCTGTAGTAGCA-30
(nucleotides [nt] 79–96); IN shRNA3, 5 0-GTAGACTGTAGCCCAG-
GAA-3 0 (nucleotides [nt] 158–176); IN shRNA4, 5 0-GAGA-
TCAGGCTGAACATCT-3 0 (nucleotides [nt] 495–513). All of the
position numbers of the IN nucleotide sequence described here corre-
spond to those of the HIV-1 IN cDNA sequence (GenBank accession
no. AF078150). A pair of complementary oligonucleotides that con-
tained BamHI site, sense strand of target site, 9 nts hairpin loop se-
quence (TTCAAGAGA), anti-sense strand of target site and HindIII
site were prepared for vector construction according to the manufac-
turer’s instruction. All constructs were veriﬁed by sequencing. The pSi-
lencer 2.0-U6 Control vector from Ambion was used as a negative
control.2.3. Cell culture and transfection
HeLa cells (ATCC) were cultured and maintained in RPMI contain-
ing 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml of strep-
tomycin–penicillin (Invitrogen) at 37 C in an 5% CO2 incubator.
Twenty-four hours before transfection, 1 · 106 cells were seeded onto
a 6-well plate in RPMI containing 10% FBS. EGFP-C1-IN expression
vector and each of pSilencer construct or control plasmid were co-
transfected into HeLa cells using Lipofectamine+Plus reagent (Invitro-
gen) in accordance with the manufacturer’s instruction. Forty-eight
hours after co-transfection, the expression of EGFP tagged IN was
screened by means of ﬂuorescence microscopic analysis and Western
blot analysis.ation of European Biochemical Societies.
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For cellular localization of IN, the glass plate containing transfected
cells were rinsed with phosphate-buﬀered saline, pH 7.5 (PBS). The
glass plate was mounted on the stage adaptor (Model: SA-20L/Z) with
growth medium. Fluorescence imaging was carried out using a Leica
TCS-NT confocal microscope. For RNAi detection, ﬂuorescence
imaging was carried out using a Nikon UV microscope directly in a
6-well plate after washing with PBS and staining with DAPI.2.5. Western blot
The transfected cells were rinsed with PBS and trypsinized. The cell
pellet was collected by centrifugation at 5000 · g for 5 min at 4 C,
washed with PBS twice and collected by centrifugation. The cell extract
was prepared by lysing in 1% SDS and cleared by centrifugation at
15000 · g for 5 min at 4 C. The protein concentration of cell lysate
was measured using the BCA protein assay kit (PIERCE) with bo-
vine serum albumin as a standard in accordance with the manufac-
turer’s instruction. An amount of 30 lg protein was subjected to
12% SDS–PAGE and then transferred to an immobilon-P transfer
membrane (Millipore). After blocking with blocking buﬀer (5% non-
fat milk in 1· Tris-Buﬀered Saline Tween-20 (20 mM Tris–Cl,
150 mM NaCl and 0.05% Tween-20)) for 1 h, membrane were incu-
bated with EGFP antibody (BD Living Colors A.v. monoclonal anti-
body (JL-8)) or b-actin antibody (Sigma) overnight at 4 C. After
incubation with alkaline phosphates (AP) conjugated secondary anti-
bodies and target protein was visualized with BCIP/NBT solution.
Band intensity was measured using the AlphaEase FC Stand Alone
program (Alpha Innotech Corpoation).2.6. HIV replication analysis
The proviral construct bearing a luciferase reporter gene in place of
the viral nef gene, pNL-Luc-ER+ [18,19] was co-transfected with the
selected HIV-1 IN shRNA expression vectors (3 lg), pSilencer 2.0-U6
negative control or pBluescript Tat shRNA positive control, in 293T
cells using FuGENE 6 transfection reagent (Roche) [20]. After 48 h,
HIV virus produced by the proviral construct was measured by
ELISA (ZeoptoMetrix Corp., Buﬀalo, NY) against viral surface
antigen p24Gag released into the culture ﬂuid. Gag viral proteins were
detected by Western blotting using appropriate antibodies, HIV-1
Gag-p24 (V107) monoclonal antibody [21] and HIV-Gag polyclonal
antibody (eENZYME) and was performed as mentioned in Section 2.5.3. Results
3.1. Expression of active EGFP tagged IN in HeLa cells
To facilitate the screening of the RNAi eﬀect, EGFP-IN
expression vector was constructed to provide a reporter system
for monitoring the RNAi function. Expression of EGFP-IN
was analyzed by both ﬂuorescence localization and immuno-
blotting (Supplementary 1). The expression of EGFP in HeLa
cells was evenly distributed within the cells. In contrast, expres-
sion of EGFP-IN was preferentially localized in the nucleus.
Globular protein larger than 50 kDa is limited to import into
nucleus through nuclear pore complexes (NPCs) by passive
diﬀusion [22]. The immunoblot analysis for EGFP shows that
the molecular weight of EGFP-IN fusion protein is 60 kDa.
The EGFP-IN localization demonstrated that active IN was
expressed since nuclear localization signal (NLS) was present
within IN at J161-I173 [23] to mediate the nuclear importation.
The result indicates that The EGFP-IN localization in live cell
imaging was considered a fast screening to demonstrate the
shRNA against integrase.
3.2. Inhibition of HIV-1 integrase protein expression by shRNA
expression constructs
Four diﬀerent target regions were selected for the shRNA
vectors construction and the locations of the four shRNA tar-get sites in the HIV-1 IN are shown in Fig. 1A. Monitoring the
amounts of ﬂuorescence expressed in transfected HeLa cells
were used as fast screening of the RNAi eﬀect against IN.
As shown in Fig. 1B, observable reduction of ﬂuorescence
was detected in HeLa cells transfected with pSilencer IN
shRNA 1 and pSilencer IN shRNA 4 constructs compared
with the pSilencer 2.0-U6 Control. In contrast, pSilencer IN
shRNA 2 and pSilencer IN shRNA 3 had similar amounts
of ﬂuorescence. The RNAi eﬀect was further conﬁrmed by
IN expression analysis using immunoblotting and the inhibi-
tion of each shRNA was calculated after measurement of the
band intensity. The results are shown in Fig. 1C. Virtually
no IN was detected and over 90% of inhibition was obtained
in the cell lysate that expressed shRNA 2 and 4 (lanes 3 and
6). We further tested the eﬀectiveness of both potent shRNA,
shRNA 1 and 4, on EGFP-IN suppression by using various
amounts of shRNA expression vector in the co-transfection.
To compensate for the eﬀect on transfection eﬃciency due to
diﬀerent total amounts of plasmid, pSilencer 2.0-U6 Control
plasmid was used to keep the total amounts of plasmid at
the same level. Through Western blot analysis, IN suppression
by shRNA was obtained in a concentration-dependent manner
and is shown in Fig. 2A. HIV-IN suppression was only de-
tected by using 0.625–1.25 lg of pSilencer IN shRNA 1
(pEGFP-C1-HIV-IN: pSilencer ratio in 1:2.5–1.5), suppression
was greatly reduced below this range of concentration of pSi-
lencer used. Total suppression of HIV-IN was achieved at a
concentration of pSilencer IN shRNA 4 as low as 0.1 lg
(pEGFP-C1_HIV-IN: pSilencer ratio in 1:0.6). Furthermore,
shRNA 4 showed a higher eﬀectiveness on IN suppression
than that of shRNA 1 in the logarithmic plot in Fig. 2B. Since,
a lower IC50 value was observed by using shRNA 4 (400 ng)
than that of shRNA 1 (9.3 ng).3.3. shRNA directed against IN suppresses single round cycle of
HIV-1 replication
The potent IN shRNAs, shRNA 1 and 4, were chosen for
further analysis to demonstrate their ability to suppress HIV
replication. Two of the potent shRNA constructs with lucifer-
ase-expressing HIV-1 construct, pNL-Luc-ER+ into 293T
cells were co-transfected and the amount of p24Gag antigen re-
leased into the culture ﬂuid 48 h after transfection was mea-
sured. As shown in Fig. 3A, both of the control, pBluescript
and pSilencer (lanes 2 and 4) only slightly aﬀected virus pro-
duction compared with that in proviral vector only (lane 1)
and the eﬀect of both are similar. High suppression of HIV
synthesis was observed in the positive control of pBluescript
Tat shRNA (lane 4) and showed 80% reduction relative to
the pBluescript control (lane 3). In the case of our two pSilen-
cer constructs, it was found that both pSilencer IN shRNA 1
and pSilencer IN shRNA 4 constructs could inhibit new
HIV-1 production in the range about 70–80% (lanes 5 and 6)
compared to the untreated sample and IN shRNA 4 provided
a better suppression of HIV replication than IN shRNA 1. The
suppression of HIV synthesis using shRNA targeting IN re-
gion is only slightly weaker than that targeting tat. These re-
sults suggest that shRNA targeted against IN region
signiﬁcantly suppressed a single replication cycle of HIV-1.
In addition, we examined that whether the infection ability
of newly formed virus is being reduced due to the suppression
of HIV-IN after RNAi by infecting an equal amount of
Fig. 1. (A) Schematic diagram of HIV-1 IN. Triangles below the diagram indicated the locations of the four shRNA target sites in the HIV-1 IN. (B)
Fluorescence imaging of the eﬀect of shRNAs on EGFP-IN expression. HeLa cells were transfected with pEGFP-C1-IN and various shRNA
constructs (pSilencer constructs) in 1:5 (w:w) ratio. After forty-eight hours, cells were examined microscopically for EGFP-IN expression (lower
panel) and DAPI staining showed that approximately the same numbers of cells were present (upper panel). (C) Immunoblot analysis of shRNA
expression constructs (pSilencer) directed against EGFP-IN expression in HeLa cells. Forty-eight hours after transfection, the cells were harvested.
Then samples were immunostained with anti-EGFP monoclonal antibody (Clontech) (upper panel) or b-actin monoclonal antibody (Sigma) (lower
panel). After incubation of the sample with AP-conjugated secondary antibodies, target band was visualized with BCIP/NBT solution. Band intensity
was measured using the AlphaEase FC Stand Alone program (Alpha Innotech Corpoation). Means and standard deviations from three
independent experiments are shown.
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HeLa cells [20]. Forty-eight hours after infection, viral mRNA
expression was monitored by measuring the level of luciferase
activity as shown in Fig. 3B. About 50% of viral mRNA
expression reduction was observed in the virus particles that
produced from the cell with pBluescript Tat shRNA transfec-ted (lane 4). In contrast, no signiﬁcant viral mRNA expression
was reduced in pSilencer treated virus. This suggests that virus
infectivity was suppressed with shRNA directed against tat.
However, the escaped virus synthesized in the cells transfected
with shRNA directed against HIV-IN still contain infectivity
and the presence of integrase or integration ability.
Fig. 2. Eﬀectiveness of pSilencer IN shRNA 1 and pSilencer IN
shRNA 4 on HIV-1 integrase inhibition at various concentrations. (A)
RNAi eﬀect on HIV-1 integrase was analyzed by co-transfection of
0.25 lg pEGFP-C1-HIV-IN with pSilencer Control (Lane 1) or
various amounts of pSilencer IN shRNA 1 or pSilencer IN shRNA
4 (lanes 2–9: serial dilution from 1.25 lg to 2 ng) in 24-well tissue
culture plate. The total amount of vector transfected was normalized
to same amounts by pSilencer Control. Cells were collected after 48 h
post-transfection. An amount of 15 lg sample lysate was loaded in
12% polyacrylamide SDS–PAGE and Western blotting was performed
by using GFP monoclonal antibodies. Percentage of inhibition of each
amount of pSilencer was measured by the diﬀerence between the band
intensity of +ve control and sample after normalized by the band
intensity of b-actin. (B) Logarithmic plot of HIV-1 integrase inhibition
against concentration of shRNA expression vector. Means and
standard deviations from three independent experiments are shown.
Fig. 3. shRNA directed against IN suppresses HIV-1 replication and viral g
was cotransfected with the 3 lg of various shRNA expression constructs o
measured after 48 h. (B) Viral gene expression. An amount of 20 ng (p24Gag an
Luc-ER+ and shRNA expression constructs was used on HeLa cell infecti
relative luciferase activity was calculated by comparing the lucifaerase activit
which was deﬁned as 100 relative light units (RLU). Means and standard d
3256 T.S. Lau et al. / FEBS Letters 581 (2007) 3253–32593.4. shRNA directed against IN aﬀects the formation of Gag
encoding proteins
Since the infectivity of the newly formed HIV was not af-
fected by the shRNA against IN (Fig. 3B), it is suggested that
the abolishment of HIV replication maybe through pathways
other than a direct inhibition of HIV IN. GagPol is the precur-
sor of the IN, we further analyzed the Gag expression to testene expression. (A) HIV-1 replication. pNL-Luc-ER+ proviral DNA
r controls. The concentration of p24Gag antigen in culture ﬂuid was
tigen) of HIV produced in the 293T cells that co-transfected with pNL-
on. After 48 h, luciferase activity of the cell lysate was measured. The
y with that produced from the mock control (pNL-Luc only) (lane 2),
eviations from three independent experiments are shown.
Fig. 4. Gag viral proteins expression analysis in the presence of
shRNA against IN. Immunoblot analysis of Gag viral protein in 293T
cells co-transfected with pNL-Luc-ER+ proviral DNA and 3 lg of
various shRNA expression constructs or control. The transfected cell
lysates were subjected to Western blot analyses with anti-gag
polyclonal antibody, anti-gag p24 (V107) monoclonal antibody or b-
actin monoclonal antibody. b1: Gag Pr55, b2: MA-CA-SP1 and b3:
CA.
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tion in the presence of the shRNA against IN. The amounts
of Gag encoding proteins in 293T cell were analyzed by Wes-
tern blotting after co-transfection of both viral and shRNA
constructs as mentioned in Section 3.3 and the result was
shown in Fig. 4. The amount of Gag Pr55 precursor (Fig. 4,
b1) was not aﬀected very much but the gag components, the
MA-CA-SP1 (Fig. 4,b2) complex and CA (Fig. 4,b3) protein
were reduced at various levels in the presence of shRNA
against tat or IN using anti-gag polyclonal antibody and anti
p24 monoclonal antibody. The suppression level was very sim-
ilar to the results using GFP tagged HIV-IN (Fig. 2C) and
virus particles synthesis (Fig. 3A). The MA-CA-SP1 complex
(labeled asb2) can be detected by both gag and p24 antibodies
and the size is consistent with MA-CA-SP1 (MW 41 kDa;
MA-CA-SP1-NC-SP2-p6) [24]. Furthermore, MA-CA-SP1 is
produced from the proteolytic cleavage of the Gag precursor
by the HIV protease during the virus synthesis [25,26]. There-
fore it is suggested that this immunoreactive band represents
the MA-CA-SP1 complex, a premature form (p40) of Gag pre-
cursor [21].4. Discussion
RNAi technology has become a new approach in clinical re-
search, particularly in viral infectious diseases by suppression
of speciﬁc viral genes. In the present study, vector-based intra-
cellular expressed shRNAs directed against HIV-1 IN are used
in HeLa and 293T cells to examine whether it could inhibit the
expression of IN protein and further inhibit the HIV-1 virus
synthesis. We showed here that four diﬀerent shRNA against
diﬀerent regions of IN mRNA provides diﬀerent level of sup-
pression of IN protein synthesis, IN nuclear localization and
virus production. The data indicate that there is great variation
of sequence-speciﬁc RNAi to the same gene and the eﬀective-
ness of individual designed sequence to suppress targeted gene
is therefore required empirical veriﬁcation.
Some study of rational and optimization siRNA design
showed that both secondary and tertiary structures of mRNA
[27,28] and the sequence structure of shRNA [29,30] can aﬀect
the eﬃciency of shRNA on gene silencing and these factors can
partly explain variation of IN suppression observed in our
study. RNAi was more readily eﬀective and detectable for siR-
NA targeting to region of mRNA in the loop structure rather
than to the stem structure especially in the region that contains
a large loop or several loops [27,31]. By studying the mRNA
structure through the Mfold on-line server (data not shown),
the predicted HIV integrase mRNA has a loop structure found
at and around both of target regions nt 19–37 (for shRNA1)
and nt 495–513 (for shRNA 4). The siRNA targeted to these
two regions consistently produces the prominent RNAi against
HIV-IN protein synthesis in HeLa cells. In contrast, both
shRNA at region 79–96 and 158–179 were found to target
on a hairpin-like structure. Besides, three loops were found
in both target regions 19 and 495. This mRNA secondary
structure prediction might provide an explanation of stronger
RNAi eﬀect by shRNA1 and shRNA4. Furthermore, siRNAs
at both ends are important for an eﬀective gene silencing
[29,30]. Higher eﬀectiveness of gene silencing was observed in
the siRNA that contained A/U at the 5 0 end of the anti-sense
strand and RSIC complex preferred to co-operating the strandthat relatively contain a weaker 3 0 end [30]. In this study, both
shRNA1 (anti-sense sequence: 5 0-CTCATGTTCTTGGGCC-
3 0) and shRNA4 (anti-sense sequence: 5 0-AGATGTTCAG-
CCTGATCTC-3 0) contained more A/U at the 3 0 terminal
region and higher C/G content at the 3 0 end of sense-strand
of shRNA1. This may also facilitate RNAi eﬀect than the
one of shRNA2 and 3 due to better siRNA (antisense)/RISCs
co-operation.
HIV-1 IN is the key viral enzyme to control the viral geno-
mic integrate into host and for further virus production [32].
The HIV-1 IN has also been found to act as co-factor of re-
verse transcriptase [4,5]. Therefore, suppression of HIV-1 IN
can aﬀect the steps of both viral synthesis and the reverse tran-
scription. In this study of tat protein suppression by the tat
shRNA was used as positive control to demonstrate the sup-
pression of virus synthesis and viral gene expression (Fig. 3).
Since, tat is a multi-functional regulation protein. It can stim-
ulate viral replication by controlling the transcription factor
binding to the viral mRNA [33,34] and enhance the HIV-1 re-
verse transcription processing [35,36]. In the case of IN inhibi-
tion, shRNA against IN suppressed the pNL-Luc-ER+
vector-based synthesis of viral particle (Fig. 3A) in which no
integration process is needed. This result may suggest that
the shRNA somehow aﬀect the transcription or translation
of the gag-pol gene. As a result, further suppress the new par-
ticles formation during viral assembly and budding. RNAi tar-
geting the pol gene of HIV impaired the gag-pol mRNA
translation and/or Gag processing has previously been re-
ported [37,38]. Western blot analysis on level of the Gag
encoding proteins in 293T cell (Fig. 4) showed that even there
is no signiﬁcant diﬀerence in the level of Gag Pr55 precursor,
MA-CA-SP1 complex and CA protein level was reduced after
RNAi treatment. This may be due to the inhibition of gag-pol
mRNA maturation or Gag Pr55 precursor conformation as a
result of suppression of the Gag Pr55 proteolysis [25,39,40].
Previous reports have demonstrated that mutation or deletion
of IN region interrupt the formation of viral gag mRNA or
Gag encoding proteins [37,38,41] which resulted in a change
in conformation or dimerization of Gag or GagPol precursor
[42–44]. These conformational change may aﬀect the process
of virus production [41,45,46] and the virus budding [37].
MA and CA viral proteins play an important role in virus
assembly. MA is a regulator for controlling the Gag precursor
intracellular localization or traﬃcking, which target Gag Pr55
to lipid raft in the plasma membrane where the virus assembly
and packaging take place [47–49]. CA and the adjacent SP1 are
critical for Gag multimerization and virus assembly [50–52].
Assembly and budding deﬁciency was observed in MA or
CA mutated virus [51,53–55]. Therefore, we hypothesize that
shRNAs inhibit HIV replication by binding to the IN region
of gag-pol precursor as well as HIV IN mRNA. The suppres-
sion of gag-pol precursor mRNA led to an inhibition of virus
assembly and budding.
In summary, we demonstrated that HIV-IN could be a one
of the targets for inhibition of HIV replication through RNAi.
Strategy based on multiple shRNAi is now being explored as
an eﬀective gene therapy [16,56,57]. For example, a lentiviral
vector that transcribes diﬀerent HIV RNAi molecules [56],
has been generated for gene therapy in preclinical evaluation.
Thus, RNAi against diﬀerent regions of HIV viral RNA that
can signiﬁcantly suppress viral escape from RNAi will become
the method of choice in the future.
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